00:49 , Feb 16, 2019 |  BioCentury  |  Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication. With a £28 million ($37 million) series A led...
07:00 , Aug 7, 2014 |  BC Innovations  |  Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Sirtex Medical, National Cancer Centre Singapore, Singapore General Hospital deal

Sirtex partnered with the cancer center and hospital to develop cancer treatments using Sirtex's Carbon Cage Nanoparticle technology. The technology delivers radioactive substances inside of chemically inert shells that target specific cancer cells. The deal...
07:00 , Jul 19, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Phenomix Corp. San Diego, Calif. Technology: Whole animal pharmacology Disease focus: Immune and metabolic Clinical status: Preclinical Founded: 2002 by Chris Goodnow, Keats Nelms, Peter Schultz, Steve Kay, Allan Bradley and Monica Justice Corporate partners:...
07:00 , May 6, 2002 |  BioCentury  |  Strategy

Mature start-ups

Mature start-ups Company Type Date Raised (M) Description Ovation NRDO 5/2 $150.0 In-licenses under-marketed drugs for niche markets Kalypsys Spin-out 4/2 $43.0 Spun out of Novartis Research Foundation's Genomics Institute in 2001 to validate therapeutic...
08:00 , Mar 11, 2002 |  BioCentury  |  Finance

Ebb & Flow

The good news is that biotech almost kept pace with NASDAQ last week; the bad news is it has a ways to go to catch up with the composite on a year-to-date basis. The NASDAQ...
07:00 , Aug 20, 2001 |  BC Week In Review  |  Clinical News

PI-88 anticoagulant regulatory update

The Australian National University received U.S. Patent No. 6,271,215 covering methods of using sulfated oligosaccharides, including PGL's PI-88 lead compound, to prevent and treat blood clots. PI-88 is in clinical trials to treat cancer, and...
07:00 , Jun 11, 2001 |  BC Week In Review  |  Clinical News

Heparanase regulatory update

The Australian National University received U.S. Patent No. 6,242,238 covering the sequence, expression and use of mammalian heparanase. According to PGLAF, inhibition of heparanase may disrupt inflammatory and cancer disease processes. The technology is exclusively...
08:00 , Dec 4, 2000 |  BC Week In Review  |  Clinical News

PI-88 sulfated mannopentaose phosphate regulatory update

Australian National University (Canberra, Australia) received U.S. Patent No. 6,143,730 covering the preparation of sulfated oligosaccharides, including PGL's PI-88 compound that is in Phase Ib testing to treat cancer, and their use to inhibit metastasis,...
07:00 , Aug 28, 2000 |  BioCentury  |  Emerging Company Profile

Inotek: Fighting radicals

Emerging Company Profile Inotek: Fighting radicals Free radicals, or reactive oxygen species, carry an unpaired electron and can damage DNA. While other companies have focused on ways to reduce levels of oxidants or free radicals...